Avigen discontinues lead MS drug and considers options after failure
This article was originally published in Scrip
Avigen has revealed that a Phase IIb study of its lead candidate AV650 (tolperisone HCl), a small molecule for the treatment of spasticity associated with multiple sclerosis (MS), failed to reach its primary endpoint.The company will discontinue further development of the compound as well as assess its strategic options.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.